{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:06:06Z","timestamp":1794017166451,"version":"4.8.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.beha.2023.101449","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T12:52:15Z","timestamp":1676551935000},"page":"101449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults"],"prefix":"10.1016","volume":"36","author":[{"given":"William C.","family":"Temple","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-2679","authenticated-orcid":false,"given":"Michelle L.","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Burkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2141.2005.05735.x","article-title":"The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence","volume":"131","author":"Burkhardt","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101449_bib2","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101449_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/gcc.22726","article-title":"Non-leukemic pediatric mixed phenotype acute leukemia\/lymphoma: genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma","volume":"58","author":"Martin-Guerrero","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib4","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1097\/PAS.0b013e318213e90e","article-title":"Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel","volume":"35","author":"Oschlies","year":"2011","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.beha.2023.101449_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2141.2009.08006.x","article-title":"Paediatric lymphoblastic T-cell leukaemia and lymphoma: one or two diseases?","volume":"149","author":"Burkhardt","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101449_bib6","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/bloodadvances.2020001822","article-title":"T-cell lymphoblastic lymphoma and leukemia: different diseases from a common premalignant progenitor?","volume":"4","author":"Kroeze","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.beha.2023.101449_bib7","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1080\/10428194.2020.1761970","article-title":"Analysis of clinicopathological and cytogenetic differences between B-lymphoblastic lymphoma and B-lymphoblastic leukemia in childhood","volume":"61","author":"Knez","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2023.101449_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib9","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/bjh.12460","article-title":"Disseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group","volume":"162","author":"Termuhlen","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.beha.2023.101449_bib10","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.3324\/haematol.2015.139162","article-title":"Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma","volume":"102","author":"Landmann","year":"2017","journal-title":"Haematologica"},{"issue":"19","key":"10.1016\/j.beha.2023.101449_bib11","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's oncology group trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101449_bib12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/cancers13092075","article-title":"Treatment and outcome analysis of 639 relapsed non-hodgkin lymphomas in children and adolescents and resulting treatment recommendations","volume":"13","author":"Burkhardt","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.beha.2023.101449_bib13","first-page":"1214","article-title":"SFCE and the EORTC children leukemia group. Relapsed or refractory lymphoblastic lymphoma in children","volume":"63","author":"Michaux","year":"2016","journal-title":"Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.beha.2023.101449_bib14","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/pbc.25699","article-title":"Treatment of childhood T-cell lymphoblastic lymphoma-long-term results of the SFOP LMT96 trial","volume":"62","author":"Bergeron","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.beha.2023.101449_bib15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2141.2008.07320.x","article-title":"Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group","volume":"143","author":"Abromowitch","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/bjh.12042","article-title":"The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report","volume":"159","author":"Patel","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib17","first-page":"840","article-title":"Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial","volume":"44","author":"Uyttebroeck","year":"2008","journal-title":"EurJCancer"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib18","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2141.2010.08541.x","article-title":"Clinical presentation, evolution, and prognosis of precursor B-cell lymphoblastic lymphoma in trials LMT96, EORTC 58881, and EORTC 58951","volume":"152","author":"Ducassou","year":"2011","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2023.101449_bib19","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/00000478-200011000-00003","article-title":"Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement","volume":"24","author":"Lin","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"16","key":"10.1016\/j.beha.2023.101449_bib20","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.3390\/cancers14163895","article-title":"Pediatric precursor B-cell lymphoblastic malignancies: from extramedullary to medullary involvement","volume":"14","author":"Kroeze","year":"2022","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.beha.2023.101449_bib21","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1200\/JCO.2014.59.7203","article-title":"Revised international pediatric non-hodgkin lymphoma staging system","volume":"33","author":"Rosolen","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12253-013-9676-3","article-title":"Value of FDG-PET\/CT examinations in different cancers of children, focusing on lymphomas","volume":"20","author":"Bardi","year":"2014","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.beha.2023.101449_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13550-021-00804-8","article-title":"Whole-body [18F]-FDG-PET\/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation","volume":"11","author":"Kurch","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.beha.2023.101449_bib24","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00247-019-04529-8","article-title":"Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma","volume":"49","author":"Mc Carten","year":"2019","journal-title":"Pediatr Radiol"},{"issue":"7","key":"10.1016\/j.beha.2023.101449_bib25","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/RLU.0b013e318238f72b","article-title":"Roles and limitations of FDG PET in pediatric non-Hodgkin lymphoma","volume":"37","author":"Nakatani","year":"2012","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00431-013-1993-8","article-title":"The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood","volume":"172","author":"Sioka","year":"2013","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.beha.2023.101449_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2967\/jnumed.120.254110","article-title":"SNMMI procedure standard\/EANM practice guideline on pediatric 18F-FDG PET\/CT for oncology 1.0","volume":"62","author":"Vali","year":"2021","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.beha.2023.101449_bib28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/gcc.20924","article-title":"T-cell lymphoblastic lymphoma shows differences and similarities with T-cell acute lymphoblastic leukemia by genomic and gene expression analyses","volume":"50","author":"Basso","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"9","key":"10.1016\/j.beha.2023.101449_bib29","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1080\/10428190701509772","article-title":"Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?","volume":"48","author":"Uyttebroeck","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2023.101449_bib30","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/s41379-022-01085-9","article-title":"Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia","volume":"35","author":"Bontoux","year":"2022","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib31","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/leu.2010.312","article-title":"Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10","volume":"25","author":"Bene","year":"2011","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cyto.b.21518","article-title":"AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia","volume":"94","author":"Dworzak","year":"2018","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MOH.0b013e3283623c61","article-title":"Early T-cell precursor acute lymphoblastic leukaemia","volume":"20","author":"Haydu","year":"2013","journal-title":"Curr Opin Hematol"},{"issue":"14","key":"10.1016\/j.beha.2023.101449_bib34","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/bloodadvances.2021004334","article-title":"Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma","volume":"5","author":"Xu","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2023.101449_bib35","series-title":"Frequency and prognostic implications of KMT2A rearrangements in children with precursor B-cell lymphoma","author":"Au-Yeung","year":"2022"},{"issue":"8","key":"10.1016\/j.beha.2023.101449_bib36","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.clml.2017.03.299","article-title":"Philadelphia chromosome-like acute lymphoblastic leukemia","volume":"17","author":"Pui","year":"2017","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"8","key":"10.1016\/j.beha.2023.101449_bib37","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/sj.leu.2404275","article-title":"Loss of heterozygosity on chromosome 6q14-q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma","volume":"20","author":"Burkhardt","year":"2006","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2006.07.011","article-title":"Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08","volume":"172","author":"Lones","year":"2007","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.beha.2023.101449_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29926","article-title":"Diverse mutations and structural variations contribute to Notch signaling deregulation in paediatric T-cell lymphoblastic lymphoma","volume":"69","author":"Salmer\u00f3n-Villalobos","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"16","key":"10.1016\/j.beha.2023.101449_bib40","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2012-12-474148","article-title":"Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence","volume":"121","author":"Bonn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101449_bib41","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2020005381","article-title":"Integrative genomic analysis of pediatric T-cell lymphoblastic lymphoma reveals candidates of clinical significance","volume":"137","author":"Khanam","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2023.101449_bib42","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1200\/JCO.2011.39.7661","article-title":"Clinical impact of NOTCH1 and\/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma","volume":"30","author":"Callens","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101449_bib43","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/diagnostics11091594","article-title":"Prognostic role of minimal disseminated disease and notch1\/FBXW7 mutational status in children with lymphoblastic lymphoma: the AIEOP experience","volume":"11","author":"Lovisa","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.beha.2023.101449_bib44","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1097\/HS9.0000000000000641","article-title":"Toward pediatric T lymphoblastic lymphoma stratification based on minimal disseminated disease and NOTCH1\/FBXW7 status","volume":"5","author":"Trinquand","year":"2021","journal-title":"Hemasphere"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib45","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/leu.2015.203","article-title":"Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia","volume":"30","author":"Balbach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101449_bib46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/gcc.23037","article-title":"Design of a targeted next-generation DNA sequencing panel for pediatric T-cell lymphoblastic lymphoma to unravel biology and optimize treatment","volume":"61","author":"Ruether","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"issue":"24","key":"10.1016\/j.beha.2023.101449_bib47","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1200\/JCO.2010.28.3390","article-title":"Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia","volume":"28","author":"Gutierrez","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib48","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/pbc.24021","article-title":"Absence of biallelic TCRgamma deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia","volume":"58","author":"Yang","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"64","key":"10.1016\/j.beha.2023.101449_bib49","doi-asserted-by":"crossref","first-page":"107886","DOI":"10.18632\/oncotarget.22386","article-title":"Clinical impact of miR-223 expression in pediatric T-Cell lymphoblastic lymphoma","volume":"8","author":"Pomari","year":"2017","journal-title":"Oncotarget"},{"issue":"21","key":"10.1016\/j.beha.2023.101449_bib50","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1200\/JCO.2008.21.1318","article-title":"Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group","volume":"27","author":"Coustan-Smith","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101449_bib51","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1200\/JCO.20.00531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children's oncology group AALL0434","volume":"38","author":"Hayashi","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101449_bib52","series-title":"Correlation of minimal residual disease (MRD) at the end of induction (EOI) and event free survival (EFS) in T-cell lymphoblastic lymphoma (T-LL), a report from the Children's Oncology grouop (COG) trial AALL1231","author":"Hayashi","year":"2022"},{"issue":"16","key":"10.1016\/j.beha.2023.101449_bib53","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2023.101449_bib54","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.1995.13.2.359","article-title":"Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Munster Group","volume":"13","author":"Reiter","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib55","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7","article-title":"Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapy","volume":"37","author":"Wollner","year":"1976","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib56","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/1097-0142(197912)44:6<1990::AID-CNCR2820440605>3.0.CO;2-9","article-title":"Non-Hodgkin's lymphoma in children: a progress report on the original patients treated with the LSA2-L2 protocol","volume":"44","author":"Wollner","year":"1979","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.beha.2023.101449_bib57","first-page":"416","article-title":"Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report","volume":"95","author":"Reiter","year":"2000","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101449_bib58","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/pbc.24149","article-title":"Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group","volume":"59","author":"Termuhlen","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.beha.2023.101449_bib59","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/mpo.2950200204","article-title":"Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non-B-cell (lymphoblastic) lymphoma","volume":"20","author":"Patte","year":"1992","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.beha.2023.101449_bib60","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/pbc.25469","article-title":"Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma","volume":"62","author":"Pillon","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib61","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/pbc.22162","article-title":"Long-term results of AIEOP LNH-92 protocol for the treatment of pediatric lymphoblastic lymphoma: a report of the Italian Association of pediatric hematology and oncology","volume":"53","author":"Pillon","year":"2009","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib62","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2010-06-292615","article-title":"Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)","volume":"118","author":"Asselin","year":"2011","journal-title":"Blood"},{"issue":"Suppl.1","key":"10.1016\/j.beha.2023.101449_bib63","first-page":"33","article-title":"Capizzi methotrexate with BFM backbone without craniospinal irradiation is effective treatment for pediatric lymphoblastic lymphoma: results from 5 countries with I-BFM LL 09 protocol","volume":"171","author":"Sterba","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2023.101449_bib64","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the children's oncology group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2023.101449_bib65","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children's oncology group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101449_bib66","first-page":"138","article-title":"[Clinical features and prognosis of children with lymphoblastic lymphoma]","volume":"34","author":"Jin","year":"2012","journal-title":"Zhonghua Zhongliu Zazhi"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib67","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12185-014-1585-z","article-title":"Inferior outcomes of stage III T lymphoblastic lymphoma relative to stage IV lymphoma and T-acute lymphoblastic leukemia: long-term comparison of outcomes in the JACLS NHL T-98 and ALL T-97 protocols","volume":"99","author":"Kobayashi","year":"2014","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib68","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/pbc.24848","article-title":"Clinical outcome of childhood lymphoblastic lymphoma in Shanghai China 2001-2010","volume":"61","author":"Gao","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101449_bib69","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1200\/JCO.2008.19.3367","article-title":"Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group","volume":"27","author":"Burkhardt","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.beha.2023.101449_bib70","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2009.09.021","article-title":"Hematopoietic stem cell transplantation for refractory or recurrent non-hodgkin lymphoma in children and adolescents","volume":"16","author":"Gross","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.beha.2023.101449_bib71","series-title":"Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in Japan","author":"Mitsui","year":"2009"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib72","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2006-0017","article-title":"FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia\/lymphoma","volume":"13","author":"Cohen","year":"2008","journal-title":"Oncol"},{"issue":"11","key":"10.1016\/j.beha.2023.101449_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29901","article-title":"Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)","volume":"69","author":"Whitlock","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.beha.2023.101449_bib74","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bjh.14874","article-title":"Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study","volume":"179","author":"Zwaan","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2023.101449_bib75","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.beha.2023.101449_bib76","series-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): results from the phase 2 DELPHINUS study","author":"Hogan","year":"2022"},{"key":"10.1016\/j.beha.2023.101449_bib77","article-title":"Salvage therapy in early relapse of T-lymphoblastic leukemia\/lymphoma using daratumumab\/nelarabine combination: two consecutive cases","author":"Molle","year":"2022","journal-title":"Case Rep Hematol"},{"key":"10.1016\/j.beha.2023.101449_bib78","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010150","article-title":"Venetoclax for children and adolescents with acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"14","author":"Gibson","year":"2021","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib80","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.beha.2023.101449_bib81","doi-asserted-by":"crossref","first-page":"8600","DOI":"10.3390\/ijms23158600","article-title":"A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies","volume":"23","author":"Newman","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.beha.2023.101449_bib82","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.beha.2023.101449_bib83","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.20.00494","article-title":"Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from children's oncology group AALL0932","volume":"39","author":"Angiolillo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.beha.2023.101449_bib84","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.beha.2023.101449_bib85","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.beha.2023.101449_bib86","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41375-019-0606-6","article-title":"Treatment and outcome of IG-MYC+ neoplasms with precursor B-cell phenotype in childhood and adolescence","volume":"34","author":"Herbrueggen","year":"2020","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.beha.2023.101449_bib87","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2018-03-842088","article-title":"Ig-MYC+ neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas","volume":"132","author":"Wagener","year":"2018","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2023.101449_bib88","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2023.101449_bib89","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","article-title":"Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL","volume":"11","author":"Nix","year":"2021","journal-title":"Cancer Discov"},{"issue":"Suppl 1","key":"10.1016\/j.beha.2023.101449_bib90","doi-asserted-by":"crossref","first-page":"7394","DOI":"10.1182\/blood-2022-168490","article-title":"Humanized nanobody anti-CD72 CAR-T cells efficiently eliminate B-cell malignancies via improved affinity for CD72 but induce persistent antigen downregulation in vivo","volume":"140","author":"Temple","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib91","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1200\/JCO.1995.13.6.1368","article-title":"Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study","volume":"13","author":"Tubergen","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2023.101449_bib92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2023.101449_bib93","series-title":"Prognostic impact of intensified maintenance therapy on children with advanced lymphoblastic lymphoma: a report from the Japanese pediatric leukemia\/lymphoma study group ALB-NHL03 study","author":"Sunami","year":"2015"},{"issue":"6","key":"10.1016\/j.beha.2023.101449_bib94","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1038\/leu.2008.400","article-title":"Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study","volume":"23","author":"Sandlund","year":"2009","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2023.101449_bib95","first-page":"37","article-title":"Dexamethasone (DEX) versus prednisone (PRED) in T-cell non Hodgkin lymphoma (T-NHL): results of the randomized phase III trial 58951 of the EORTC Children Leukemia Group","volume":"159","author":"Uyttebroeck","year":"2012","journal-title":"Bristih Journal of Haematology"},{"issue":"3","key":"10.1016\/j.beha.2023.101449_bib96","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.2005.02.2707","article-title":"Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma","volume":"24","author":"Burkhardt","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:07:17Z","timestamp":1761498437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521692623000105"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101449","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adults","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101449","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101449"}}